Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2021
Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive CancersIgor Odintsov, Marissa S Mattar, Allan J W Lui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2021
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic <i>NRG1</i> FusionsIgor Odintsov, Allan J W Lui, Whitney J Sisso, et al.
Lung Cancer (Amsterdam, Netherlands)|November 20, 2025
Long-term outcomes of Extensive-Stage small cell lung cancer treated with chemotherapy or Chemo-immunotherapy: A propensity score adjusted cohort studyHeya Batah, Emily C Zabor, Bridget Adcock, et al.
Disease Models & Mechanisms|December 15, 2020
RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulationTakuo Hayashi, Igor Odintsov, Roger S Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor ResistanceRobin Guo, Michael Offin, A Rose Brannon, et al.
Cancer Discovery|April 4, 2018
Response to ERBB3-Directed Targeted Therapy in <i>NRG1</i>-Rearranged CancersAlexander Drilon, Romel Somwar, Biju P Mangatt, et al.
Disease Models & Mechanisms|November 29, 2021
Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signalingRoger S Smith, Igor Odintsov, Zebing Liu, et al.
Nature Cancer|September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutationsIsao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Cancer Discovery|April 17, 2023
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, et al.
Pageof 2